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Summary An overview of the application of markers for solid tumours is presented. Some of the potential
problems with general cancer tests are considered as well as the ways in which the more specific markers have
been applied. The limited specificities of markers defined so far remain a serious limitation but they have
found useful clinical application. Their use in radioimmunolocalisation provides an interesting challenge to
the physical methods of tumour localisation and the possibilities of drug targeting by antibodies are as
exciting as the difficulties are formidable. It is, I suggest, a field that will continue to evolve and be
productive.
The concept of tumour markers has widened over
the years and the term itself is much more recent
than the basic idea. In the early 1930s Zondek
clearly thought of detecting human chorionic
gonatrophin (hCG) in body fluids to diagnose
trophoblastic tumours of gestational and germ cell
origin. Monitoring the course of these tumours with
semiquantitative assays was described in the 1940s
(Zondek, 1942; Hamburger, 1958; Hinglais &
Hinglais, 1949). Now the term has come to be
applied to any means, usually of a chemical nature,
which helps to discriminate between one type of
tumour and other normal or disease states in a
clinically useful way.
In trying to present an overview of this now very
large field I shall confine myself to the major
substances on the scene, to solid tumours and
largely to our studies at Charing Cross over the
past 25 years. Much of the work to which I shall
refer has been that of many colleagues, medical and
scientific, past and present.
Tumour markers, insofar as they exist, have
potentially large applications as screening tests for
cancer, as tests for cancer in the symptomatic
patient, as a means of monitoring the course of
disease and of detecting relapse at an early stage, in
targeting isotopes to localise tumours and possibly
in directing therapeutic agents.
It seems unlikely that a single marker will be
ideal for all these applications even with respect to
a single type of cancer; indeed the requirements for
different purposes may be mutually exclusive.
Markers exist which can demonstrate all these
different roles but unfortunately they have been
identified so far, in clinically useful forms, for only
a modest proportion of tumours.
Cancer tests
Rather little has been said about cancer tests in
general although it is not uncommon for scientists
to tumble on some phenomenon that appears to
distinguish patients with cancer from other people
and before long the scientist is liable to be carried
along on a wave of blind conviction and messianic
fervour. A test that would reliably detect cancer in
the general sense at any early stage, and one that is
serological in nature and therefore suitable for
automation, might have incalculable value and vast
application. But the key words here are "reliably"
and "early" so I want to focus not on the details of
the tests that have been proposed but on the
question of what might be useful and what might
be a liability. For there can be no doubt that a
general "cancer test" that reaches clinical practice is
bound to have far reaching consequences.
The possibility of a "test" that would detect the
presence of all or most forms of cancer in the
human subject rests on the proposition that
neoplasia in all its many forms results in a unique
change in a component of body fluids or in a host
response phenomenon. Whilst some of the tests
have resulted from formal attempts to identify a
common tumour antigen, others have been the
product of serendipity. The tests known to me are
listed in Table I. They have all been immunological
in nature and each has therefore implied a
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Table I Cancer tests (description and references)
Makari Skin Test
Makari, 1955; Tee & Munson, 1977
Lewis Test
Lewis et al., 1966, 1971
T Globulin
Tal & Halperin, 1970; Herberman, 1977
Macrophage Electrophoretic Mobility Test
Field & Caspary, 1970; Bagshawe, 1977
Tissue Polypeptide Antigen
Bjorklund, 1980; Menendez-Botet et al., 1978
Structuredness Cytoplasmic Matrix Test
Cercek & Cercek, 1977; Mitchell et al., 1980
Anti-Malignin Test
Bogoch & Bogoch, 1979
Tennessee Antigen Test
Potter et al., 1978; Pentycross, 1982
Tumour-Tek Test
None given
supposedly common yet unique antigenic
determinant. Several of the proposed tests have
been evaluated in our laboratory and with respect
to the others my comments are based on published
evidence. Some have been well reviewed by
Herberman (1977).
Some of the papers reporting "cancer tests"
provide inadequate technical information to satisfy
even the most casual reviewer and by omission or
implication there are secret ingredients in the recipe
which are guarded for commercial exploitation.
Some tests have been widely promoted without any
pretence to appear in the scientific literature. In one
case literature references are cited but those who
take the trouble to look these up find papers on
completely unrelated tumour markers.
No such complaints can be levelled at the
proponents of the Macrophage Electrophoretic
Mobility or MEM test (Field & Caspary, 1970) and
the Structuredness of Cytoplasmic Matrix or SCM
Test (Cercek & Cercek, 1977). Both of these tests
were based on sensitisation of the cancer patients'
lymphocytes to myelin basic protein or a closely
related substance and their proponents cooperated
with others who later became involved in further
evaluation. The first impressive claims, which in the
case of the SCM tests, were for better than 99.5%
correct results, were followed by confirmatory
reports (Pritchard et al., 1972, 1978). Nevertheless,
their evaluation took several years to achieve and
the cost probably ran into several millions of
pounds before it became clear that they were
unlikely to be clinically useful (Bagshawe et al.,
1977; Mitchell et al., 1980; Balding et al., 1980).
Better controlled initial clinical studies would have
avoided this expensive and traumatic process.
Moreover there is the danger that, if a test fails
to be substantiated, the underlying phenomenon
will not be properly investigated, even though the
phenomenon may be of interest.
The sensitivity of a test is usually defined as the
percentage of people with the disease who have a
negative response and specificity as the percentage
of those who do not have the disease but who give
a positive response. For brevity we describe these as
false negative and false positive rates. It is
commonly suggested or implied that a test which is
90% accurate meaning one that has a false
positive rate of 10% and a false negative rate of
10%-could be useful clinically.
We can consider the situation that might arise if
a cancer test of this accuracy were to come into
clinical practice even though clinicians might be
fully aware of its limitations. A false negative rate
of this magnitude would no doubt create some
problems but its advantages could probably
outweigh the false security which it might engender.
Moreover, if there were some other factor meriting
further investigation the negative result would be
put into proper perspective. It could, if sufficiently
sensitive, contribute to early diagnosis.
The false positive cancer test would however be
quite a different problem. We can envisage a
situation where most patients presenting with
symptoms that might possibly be due to malignant
disease would be given the test. Some patients
would ask for it as some now do for pregnancy
tests. And who would deny them? What confidence
can the clinician have that his legal colleagues
would fail to see their opportunities if such a test
had not been performed on a patient subsequently
found to have cancer? The threat of litigation could
override other considerations. And what then of the
patient who in the absence of clinical evidence of
malignant disease, is found to have a positive test?
Would it be possible to ignore it even if all else
proved normal. Repeating the test might help but
given that the false positives were not transient or
random the problem would be where to stop the
procession of investigations. Patients would have to
be told they had a positive test for cancer and new
symptoms might well develop. Further
biochemistry, chest radiography, contrast studies,
cytology, ultrasound, whole body CT scanning and
multi-orifice endoscopies would lie in wait for the
unfortunate victim. Some of these investigations
themselves carry penalties and the doctor might be
held imprudent to have ordered them. If the
prevalence of cancer were 2.5/1000 in a screened
population then with a 10% false positive rate there
would be 39 false positives for every true positive.HAMILTON-FAIRLEY MEMORIAL LECTURE 169
It is I think not inconceivable that there could
result a significant shift in the use of medical
resources from the management of the sick to the
investigation of the healthy.
Even so, the temptation to pharmaceutical
houses to launch into this field is almost
overwhelming. There is therefore a responsibility on
those involved in evaluating such tests to be
particularly cautious in their enthusiasm. Many
evaluations end with some blandishment such as
"this should prove a useful test" simply because a
significant difference has been demonstrated
between a group of cancer patients, often with
advanced disease, and a group of controls. The
controls may be normal healthy people and rarely
are they composed of those patients with obscure
non-malignant diseases that do present difficult
diagnostic problems. A statistically significant
difference existing between cancer and non-cancer
groups is of limited value when translated to the
individual patients (Gray et al., 1982; Pentycross
1982). How does it help the doctor confronted by
the patient with an unexplained symptom, such as
anorexia? "You have a positive cancer test, but
don't worry there's a one in ten chance it's wrong"?
It would be reckless to try to set a level of
accuracy at which a cancer test would become an
acceptable asset. The more reliable the test the less
frequent the problem of the false positive but the
corollary of this would be the greater necessity to
investigate every positive. No doubt there could be
a point where benefits would exceed the penalties
and it can only be hoped that reagent control
agencies as well as pharmaceutical companies will
continue to exercise great caution.
It is worth considering that these problems might
be peculiar to the "all or none" concept of a single
general cancer test. It is possible that if the same
quality of information were to be ascertained from
a series of independent tests requiring evaluation by
some form of multivariate analysis then it might be
less emotive. The elements of clinical judgement
and uncertainty and the probabilities of different
methods of data analysis might ease the situation.
It is just possible that there would be more latitude
in making the decision whether to perform the tests
and the action that would need to be taken in the
event of a high probability result being obtained.
Markers for particular types of cancer
I have argued that a general test for cancer would
need to have a very high degree of specificity but
when we turn to tests for individual tumours we
can turn that argument on its head. If we waited
for absolute specificity there would be no tests at
all. Yet there are some clinical situations where the
use of a marker associated with particular tumours
can be decisive even in primary diagnosis. "Acute
orchitis" with a positive test for hCG or AFP is not
"acute orchitis", but we still see young men die
because their doctor didn't ask for a simple test.
And a positive pregnancy test persisting for 6
months in a young woman with a flat abdomen
indicates something more sinister than a pregnancy.
Claims have been made for highly specific tumour
markers but none so far have withstood close
scrutiny and a tumour specific marker may well be
defined as one that hasn't been properly
investigated. Present serum markers may also be
used in the primary diagnosis situation to
distinguish between say a seminoma and an
embryonal carcinoma of the testis or to distinguish
a medullary carcinoma of the thyroid before
surgery. Here we are not confronted by the emotive
content of the general "cancer test" and the
challenge is to exploit whatever information is
available.
Human chorionic gonadotrophin was perhaps the
first tumour marker to have been identified, also it
arguably remains the most specific. Yet it is of
course far from specific in the sense that it is also a
marker for pregnancy and for a range of tumours
that produce it as an ectopic product.
As a serological marker for trophoblastic activity
hCG has formed the basis of the only practical
biochemical screening programme yet established.
Thus, in the UK patients with pregnancies resulting
in hydatidiform mole are screened on the basis of
their hCG values in serum or urine and those 10%
or so who require treatment by various criteria can
be clearly identified. This is the ideal situation for
screening; a well defined population of young
adults at high risk, for a limited period, to a
potentially fatal tumour, which if identified at an
early stage can almost always be eradicated and in
most cases without significant toxicity or
impairment of fertility (Bagshawe et al., 1973;
Begent & Bagshawe, 1983).
It is difficult at present to identify any other
possible primary tumour screening operations based
on serological markers. Alphafetoprotein (aFP) was
looked at as a means of detecting early hepatomas
in a high risk population but found wanting with
the methods then available (Purves, 1973) and a
similar result has been reported recently (Watanabe
& Nagashina, 1981). Although it seems likely that
we will have to await new markers before further
biochemical screening can be undertaken for cancer
there is the potential use of viral screens to identify
high risk populations for hepatocellular and
nasopharyngeal carcinomas and the use of occult
blood tests to detect colorectal cancer.170 K.D. BAGSHAWE
Prognosis
The concentration of a secreted tumour product in
serum should ideally reflect the total body burden
of viable tumour. For some markers at any rate
this appears to be true and for hCG this has been
amply confirmed in the clinical context (Bagshawe,
1969) as well as in the nude mouse xenografted
with choriocarcinoma (Searle et al., 1981).
Production of hCG in vitro and by small residual
tumour masses in vivo has been studied and has
provided a crude approximation which allows us to
relate hCG values to the body burden of viable
cells (Bagshawe, 1973). On the other hand the
correlation between serum concentration and
tumour bulk is much less well defined for CEA
both in the human subject and in the nude mouse
xenografted with CEA producing human colonic
cancer (Lewis & Keep, 1981).
It is widely accepted that, other things being
equal, the greater the total body burden of tumour
the worse the prognosis and this was illustrated in a
review of some 317 patients with trophoblastic
tumours treated between 1957 and 1973 (Bagshawe,
1976). Whereas in those with hCG values (24h
urine excretion rates) between 103 and 104 IUI-
the fatality rate was 3%' it rose progressively with
increasing hCG values and was >60% in those
with hCG values exceeding 106 IUIF.
In the germ cell tumours we have a more
complex situation. The values for hCG and aFP
reflect the body burden of trophoblastic and yolk
sac elements respectively and although these
elements do not constitute the full array of tissue
differentiation they are the most aggressive
components of the tumour. Here therefore the
markers reflect the duality of volume and
aggressiveness which determine in large measure the
patient's prognosis with present methods of therapy.
Thus in our series which consists mainly of patients
with bulky disease the markers reflect prognosis
more surely than bulk itself as assessed
radiologically. (Germa Lluch et al., 1980; Newlands
et al., 1983). CEA and some other markers also
deserve mention in the context of prognosis but it
would be difficult to deal with such a complex scene
with acceptable brevity.
Monitoring
The first attempts at monitoring the course of a
tumour with hCG measurements occurred in the
1930s. With the introduction of chemotherapy in
the 1950s bioassays provided the first insight into
the response pattern of advanced choriocarcinomas
and the ability to follow them down to a volume of
tumour not detectable by radiological methods.
(Hertz et al., 1958; Bagshawe & Brooks 1959).
Similarly for the germ cell tumours hCG and
aFP provide a guide that is sensitive but has still to
be assessed in the context of radiological evidence.
For hepatoma we have of course a good marker in
aFP but this tumour illustrates the point that a
marker only shows its real value when there is
effective treatment.
It would serve no useful purpose here to review
superficially the other markers in current clinical
use. Appreciation of their limitations is important
but should not obscure recognition of the situations
where they can be useful. New markers are
commonly proposed and the promise of the
monoclonal antibody revolution has still to be felt
in the solid tumour clinic. The possibility that
epitopes defined by monoclonal antibodies may
occur on more than one protein is an additional
twist on the road to specificity.
More specific markers may be found, and the
search for them must be continued but the
challenge is to learn to exploit the limited
specificities we already have and can expect to have
more of in the future. Immunocytochemistry mainly
with enzymatic methods has become established,
even if somewhat patchily, as an aid to
histopathology. Whilst pathologists find it valuable
its universal acceptance is likely to be dependent on
better markers becoming available for the solid
tumours. It is notable that whereas serum CEA is
elevated in only about 50% of patients with
colorectal cancer, it has been demonstrable by
immunocytochemistry in tumour tissue in virtually
all cases studied including a series of 50 cases at
Charing Cross. It is perhaps the regular
demonstration of such markers in human cancer
that has triggered interest in the field of targeting.
Radioimmunolocalisation
Since the studies of Pressman & Korngold (1953),
Quinones et al. (1971) and Primus et al. (1973)
showing the localisation of radiolabelled antibodies
in experimental tumours the feasibility of radio-
immunolocalisation (RIL) in man has been amply
demonstrated (Goldenberg et al., 1978; Dykes et al.,
1980; Mach et al., 1980; Searle et al., 1980; Farrands
et al., 1982). In our experience of almost 200 such
scans at Charing Cross using mainly hCG or CEA
as the target antigens, it can be said that there have
been some instances where the technique has
provided clinically useful information, leading in
some cases to successful tumour resections, where
other methods of tumour localisation including
computerised tomography and ultrasound had
failed or had been equivocal (Begent et al., 1982).
Obviously the ultimate question is how RIL
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of tumour localisation. All imaging methods are in
an evolutionary stage. In addition to radionuclide
scanning and ECAT scanners we see sontinued
developments in CT scanning and ultrasound, and
the emergence of nuclear magnetic resonance
(NMR) (Smith, 1981) and positron emission
tomography (PET) (Hoffman et al., 1976). It is
clearly going to take many years for each of these
highly complex developments to reach the peak of
efficiency. The problem of evaluationg them
individually and of determining the most effective
and economic way to deploy these powerful tools in
relation to each other is daunting. Large tumour
masses are detectable at virtually any site by
existing techniques and we are essentially looking
for the means to detect smaller tumours particularly
within the abdomen and pelvis. One important
aspect of RIL lies in the possibility of
discriminating between viable cells which are
actively synthesising the antigenic target and dead
tumour which is not. Volume changes are
important but non-volume changes consequent
upon therapy may also be detectable. The CT
density of a lesion may help in the identification of
necrotic tissue up to a point, and fine needle biopsy
when feasible can be decisive but sampling
questions are frequent with this technique. It is
possible that PET or NMR may prove more
sensitive means of detecting metabolic changes in
tumours than RIL but the question is unlikely to be
resolved for some years.
Another aspect of the relationship between these
new techniques of tumour localisation lies in their
relative merits for looking at a large part of the
body. Thus the gamma camera has the advantage
of a wide field of view including the brain and the
potential for relatively easy identification of
antibody localising sites. The high resolution of CT
and NMR methods calls for a large number of
"cuts" each of which requires careful and expert
examination. A reasonably reliable method of whole
body scanning may, even if somewhat anatomically
imprecise, provide a useful preliminary screen
directing the more precise tomographic tools to
specific anatomical sites in selected patients.
Anatomical resolution by RIL is likely to
improve with the substitution of other isotopes such
as 1"'in or 1231 for 131I. Even so there may be no
ideal isotope. Indium may have specific limitations
for the detection of hepatic metastases and the
shorter half life of 123I imposes some logistical
problems.
The antigenic targets studied by RIL to date
have mainly been the secreted antigens hCG, aFP
and CEA but there are interesting studies also with
melanoma antigens (Larson et al., 1983), and other
antigenic targets (Epenetos et al., 1982; Farrands et
al., 1982). The ability to achieve tumour localisation
in the presence of high concentrations of antigen in
serum and other body fluids is interesting but we
do not yet know whether it is better to have
antibodies of high avidity or whether a particular
immunoglobulin class is superior for this purpose,
or whether antibody fragments are advantageous
compared with intact immunoglobulin. Although
there would seem to be no intrinsic advantage in
monoclonal rather than polyclonal antibodies for
RIL, monoclonals have some obvious practical
advantages in helping to resolve some of these
questions. Moreover, if multiple antigens make
better targets than single antigens then monoclonals
offer us the unequivocal advantages of controlled
and reproducible reagents.
We do not yet know whether it is better to have
as the target a secreted antigen or one bound to the
cell membrane. It is often assumed that the latter
would be better but few non-secreted markers of
comparable specificity have been adequately
studied. Clearly the central problem with RIL is to
achieve the maximum contrast between tumour and
background. Antigenic expression and secretion
may be open to modification (Biquard & Aupoix,
1978; Browne & Bagshawe, 1982). The
"subtraction" technique (Goldenberg et al., 1978)
which first made RIL possible has the serious
disadvantage that it is somewhat arbitrary. It may
be that certain classes of antibody localise in
tumours and yet clear quickly from body fluids.
Alternatively, the removal of circulating antibody
may be accelerated by other means. This has been
shown both in animals and in man by giving a
second antibody directed at the first, radiolabelled
antibody. We have found that by encapsulating the
second antibody in liposomes the concentration of
first antibody in serum is rapidly reduced through
uptake in the reticuloendothelial system without a
comparable reduction in the tumour concentration.
Some other potential hazards of immune complex
formation may also be minimised by this technique
(Begent et al., 1982).
The fact that antibodies can be shown to localise
in tumours both by immunocytochemistry and by
RIL has been a spur to therapeutic studies.
Ironically, if antibody targeting in the therapeutic
context were to succeed it would of course provide
the lowest cost solution to the imaging problem by
largely extinguishing the need for tumour
localisation.
Drug/Antibody targeting
The complement dependent cytotoxic action of
antibodies has long been known but has proved
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there has been interest in the possibility that one
class of IgG (Herlyn et al., 1980; Sears et al., 1982)
or the use of univalent antibody (Glennie &
Stevenson, 1982) may be cytotoxic. Nevertheless
most interest at present focuses on drug/antibody
combinations. The antibody targeted approach
results from our failure so far to develop cell
inhibiting agents of sufficient selectivity so the
principle here is to produce a favourable differential
distribution of non-selective agents.
A substantial literature has built up in the
past two decades around the possibility of
developing anti cancer agents with improved
therapeutic/toxicity ratios by combining a drug or
isotope with an antibody directed at a tumour
antigen. The idea, of course, goes back to Ehrlich.
It will not be possible to review this field in depth
here but since our studies in tumour markers have
from their beginning been broadly directed towards
this possibility I propose to comment on the
present scheme. Any idea that one has simply to
couple a cytotoxic drug to an antitumour antibody
to achieve a highly selective antitumour agent is
dispelled by the number of papers reporting such
approaches at the experimental level and the
paucity of published clinical results (Ghose et al.,
1982; Dullens et al., 1979; Rowland et al., 1975).
The fact that only a fraction of 1% of administered
antibody has been retained in tumours (Mach,
1980) emphasises just one of the difficulties. In RIL
the gamma camera and computer enhance the
distinction between tumour and background but in
drug targeting there is the additional problem of
absolute concentrations and the time for which they
are maintained both in tumour target and in
susceptible normal tissues.
One assumption that has been widely made in
these studies is that antibody or antibody/conjugate
directed at a tumour-associated antigen finds its
way to the cell membrane and becomes membrane
bound. In reality it seems more analogous to a
leaking sieve than a magic bullet. Thus, the drugs
selected have been such as to require penetration
into the cytoplasm of the target cells and the
popularity of the ribosome-inactivating proteins
such as the A chain of diphtheria toxin and ricin
illustrate this. It is of course one thing to
demonstrate binding to a cell surface in vitro, or to
ascitic tumour cells by i.p. injection, and another to
demonstrate that an intravenously-delivered
antibody conjugate reaches the cell membranes of a
high proportion of cells in a solid tumour in
effective concentration. An order of magnitude
difference between in vitro and in vivo
concentrations has been found in one study (Larson
et al., 1983). It might be expected that the ability of
an antibody to reach the cell surface depends on
whether the antigen is secreted or freely shed.
Autoradiographic studies in our laboratory with
anti-CEA in mice xenografted with human colonic
tumours have shown that the highest concentration
of antibody is in the extracellular fluid space and in
extracellular debris (Lewis et al., 1982). At the same
time this study does, however, suggest that a small
amount of antibody is internalised by tumour cells
and the effect is specific in that more anti-CEA
than non-specific antibody localises in the
cytoplasm of CEA-producing cells.
It can be argued that the concentration of
antibody in the extra-cellular fluid space is a good
reason for not using a secreted antigen as the
target. The problem is that, so far, there is a
shortage of membrane-bound antigens which have
been characterised sufficiently to show they have
sufficient specificity for clinical purposes.
Autoradiographic studies of an antibody directed at
a supposedly membrane bound antigen appear to
show a similar distribution to that of anti-CEA
(Epenetos et al., 1982) so that even where
immunocytochemical and other studies suggest that
an antigen is membrane bound in vivo,
autoradiography is needed to confirm this. Of the
monoclonal antibodies we have tested so far only
one has shown marked affinity for binding to
tumour cell membranes.
For drugs which must penetrate the cell
membrane to exert their effect an antibody which
binds to the cell surface in vivo is a first
requirement. The in vivo distribution of antibodies
to tumour-associated antigens requires detailed
study before they can be properly used in the
clinical situation with cytotoxins. Almost 20 years
after the discovery of CEA its distribution in
normal and malignant tissues is still being defined.
The process will need speeding up. Clearly, finding
an antigen in a normal tissue may or may not be a
limitation and depends in part on whether that
tissue is vital to life. But the specificity or lack of
specificity of tumour-associated antigens remains, I
suggest, one of the main obstacles to progress.
Even with a tumour-associated membrane bound
antigen of adequate specificity there are likely to
remain other problems. Do all the stem cells
express the antigen or is it only expressed by cells
which have differentiated? HCG for instance is only
produced by syncytiotrophoblast and not by the
stem cell cytotrophoblast. Heterogeneity of antigen
expression could be a serious limitation. Again,
there is the question whether in the presence of
antibody will the antigen patch, or cap, or
modulate?
The possibility of improving the overall
specificity of the delivery system and of increasing
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at more than one antigen is already under
investigation. It is analogous to the use of
combination chemotherapy with a dispersal of toxic
effects on normal tissues but a summation of them
on the target. Also, there is the possibility of
producing hybrid antibodies with specificities for
more than one antigen (Nisonoff & Rivers, 1961)
and hybrid antibodies in which one Fab fragment
binds to the target and the other binds to the drug
(Raso, 1982).
One suggested limitation of the whole approach
is the rapid development of an immune response by
the patient to xenogeneic antibody or
antibody/drug complex. We have found that
patients treated with conventional cytotoxic agents
before or during exposure to large amounts of
rabbit or sheep immunoglobulin have not been
readily sensitized. Changing antibody species or
human antibodies may however be necessary if
treatment has to be repetitive. So far as the plant
toxins are concerned it is fortunate that there is a
wide choice.
There is also the question of antigen density on
the cell surface since this presumably limits the
concentration of antibody. For conventional
cytotoxic agents it is evident that unless a very
large number of molecules comparable to that
achieved by the free drug can be delivered into the
cell, a cytotoxic effect is unlikely to result. With the
ribosome-inactivating proteins the number of
molecules required may be quite low and possibly
less than a hundred are required to achieve a lethal
effect on a target cell; even so such concentrations
of antibody have yet to be demonstrated to be
achievable in vivo in the near 100% of stem cells
required for clinical effectiveness.
Given these difficulties with membrane-bound
antigens and agents that need to enter the cell to
exert a lethal effect we should not readily pass over
the secreted antigens as possible targets. Direct
measurements of the concentration of these
antigens in the extra-cellular fluid spaces of
tumours are not available but data can be obtained
from autoradiographic and tissue radioactivity
studies following administration of radiolabelled
antibody. Since the antibodies are concentrated at a
distance of some microns from the cell surface the
"warhead" needs to be capable of either being
selectively released within the tumour or of being
able to exert its effect at "long" range.
Long range effects may be achieved by radiation
sources. Alpha emitters such as 211Astatine have
the attraction of requiring only a very small
number of hits on the cell (Bloomer et al., 1981)
but it may prove difficult to handle the 99.9% of
isotope which doesn't get into the tumour. Studies
with "3'I-anti CEA in patients with advanced
cancer have been described (Ettinger et al., 1982)
and our calculations of radiation delivery to
tumours are in broad agreement with this report.
Small tumours may prove better targets than large
tumours. Better isotopes may be available and ways
of improving tumour to non-tumour discrimination
and of protecting normal tissue are open to
development.
Another possibility in which we have been
interested is that of using metabolite-depleting
enzymes. In conjunction with Dr R. Sherwood of
the Centre of Applied Microbiology and Research
at Porton Down we have been investigating the use
of a folate-splitting carboxypeptidase coupled to
antibodies directed at secreted antigens. An effect
on the in vitro growth of a choriocarcinoma cell
line has been demonstrated with carboxypeptidase.
Antibodies to hCG have been coupled with
carboxypeptidase whilst preserving the specific
characteristics of both molecules (Searle,
unpublished). One problem is to maintain an
effective concentration of the enzyme in the tumour
extra cellular fluid for a long enough period and it
seems likely that carboxypeptidase may achieve its
best results in conjunction with conventional
cytotoxic therapy aimed at blocking other
metabolic pathways. There are, of course, other
targetable enzymes to investigate.
One of the attractions of work in the tumour
marker field at present is the large number of
directions in which it might develop. In all
directions the obstacles are formidable and the
study of markers for the solid tumours has
presented many pitfalls and disappointments in the
last 25 years. Yet it has continued to grow and the
possibility that it may have an impact on therapy
gives the whole field new impetus. The success of
any application of tumour markers ultimately
depends on the degree of discrimination that
markers provide and it is important that the search
for such markers should continue however
monotonous the study and however frequent the
disappointment.
The Department of Medical Oncology studies have been
supported by the Cancer Research Campaign and the
Medical Research Council. I am indebted to the clinicians,
biochemists, technical and nursing staff of the
Department, my colleagues at Charing Cross and the
numerous gynaecologists, radiotherapists, surgeons and
pathologists elsewhere who have helped to make these
studies possible.174 K.D. BAGSHAWE
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